Relmada Therapeutics

Relmada Therapeutics, Inc. is a clinical-stage biotechnology company based in New York, focused on developing drugs aimed at treating central nervous system (CNS) diseases and chronic pain. The company's lead product candidate, d-Methadone, is currently undergoing Phase II clinical trials for indications including depression and neuropathic pain. Additionally, Relmada is advancing several other products, including LevoCap ER, an abuse-resistant formulation of levorphanol; BuTab, an oral formulation of buprenorphine; and MepiGel, a topical formulation of mepivacaine designated as an orphan drug. Founded in 2004, Relmada Therapeutics is dedicated to addressing significant unmet medical needs within the pain management and CNS therapeutic areas.